Neoplasms

All Conditions

Symptoms and General Pathology

Digestive System Diseases

Rare Diseases

Adenocarcinoma

Neoplasm Metastasis

Carcinoid Tumor

Appendiceal Neoplasms

Adenocarcinoma, Mucinous

Cystadenocarcinoma

Neoplasms, Cystic, Mucinous, and Serous

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Cecal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Cecal Diseases

Intestinal Diseases

Adenocarcinoma of the Appendix

Neuroendocrine Tumor

Neuroepithelioma

Anti-Infective Agents

All Drugs and Chemicals

Formaldehyde

Individuals ages 18+ years with an appendix cancer diagnosis in the United States.

Individuals ages 18+ years with an appendix cancer diagnosis seen at Vanderbilt.

Biological parents of active GAP (Social and Vanderbilt) Study participants.

Genetic profiling

Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed

Retrospective tissue procurement

GAP Study Coordinator (Rebecca B.)

Andreana N Holowatyj, PhD, MSCI

The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.

The Genetics of Appendix Cancer (GAP) Study aims to analyze hereditary factors, tumor characteristics and clinical features/outcomes among adults diagnosed with appendix cancer and their biological parents. Patients are recruited at any time after a diagnosis of appendix cancer and followed for up to 6 years after study enrollment. This cohort is enriched by robust biospecimens and data collections.

Genetics of Appendix Cancer Study

Genetics of Appendix Cancer: The GAP Study

Andreana Holowatyj, PhD, MSCI

Sponsor Investigator

Respiratory Tract (Lung and Bronchial) Diseases

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Breast Neoplasms

Colorectal Neoplasms

Esophageal Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Uterine Cervical Neoplasms

Endometrial Neoplasms

Pseudomyxoma Peritonei

Breast Diseases

Skin Diseases

Colonic Diseases

Rectal Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Stomach Diseases

Head and Neck Neoplasms

Esophageal Diseases

Uterine Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Stomach Cancer

Esophageal Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

SGN-STNV

Suzanne McGoldrick, MD

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors.

The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

The study will include dose escalation (Part A) and dose expansion (Part B), with multiple disease-specific cohorts and a biology cohort in dose expansion. The biology cohort will require additional biopsies. At the completion of dose escalation, up to 5 disease specific expansion cohorts and 1 biology expansion cohort may be activated by the sponsor in consultation with the Safety Monitoring Committee (SMC). Expansion cohorts in Part B will enroll subjects with selected tumors that are eligible for enrollment in Part A. The dose(s) to be examined in Part B will be at or below the maximum tolerated dose and/or the recommended dose determined in Part A. The recommended dose and/or schedule may differ between cohorts.

A Study of SGN-STNV in Advanced Solid Tumors

A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

To be summarized using descriptive statistics

ORR is defined as the proportion of subjects achieving a partial response (PR) or complete response (CR).

PFS is defined as the time from the start of any study treatment to first documentation of disease progression or to death due to any cause, whichever comes first.

OS is defined as the time from the start of any study treatment to the date of death due to any cause.

DOR is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression or to death due to any cause, whichever comes first.

Seagen Inc.

Prostatic Neoplasms

Triple Negative Breast Neoplasms

Cholangiocarcinoma

Bile Duct Cancer

Dose escalation with increasing dose levels of APL-5125 to identify Recommended Phase 2 Dose.

Possibility to expand into select populations

Up to 2 dose levels of APL-5125 in a selected population

APL-5125 is an oral drug (capsule) taken daily in 28-day cycles

APL-5125

Apollo Therapeutics

Daniela Pignataro, MD

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors

Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, electrocardiogram results.

Evaluation of tolerability parameters including dose limiting toxicities as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs and electrocardiogram results

Response is assessed per RECIST version 1.1 criteria

Evaluate PK parameters: volume of distribution

Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, electrocardiogram results

Apollo Therapeutics Ltd

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Genetics of Appendix Cancer Study	NCT05734430	Appendix Cancer Appendiceal Can... Appendiceal Neo... Appendiceal Muc... Appendiceal Ade... Appendiceal Car... Appendiceal Neo... Appendix Adenoc... Appendix Mucino... Appendix Tumor Appendix Cancer... Appendix NET Low-Grade Appen... High Grade Appe... High Grade Appe...	Genetic profili... Retrospective t...	18 Years -	Vanderbilt-Ingram Cancer Center
A Study of SGN-STNV in Advanced Solid Tumors	NCT04665921	Carcinoma, Non-... HER2 Negative B... Ovarian Neoplas... Uterine Cervica... Endometrial Neo... Esophageal Neop... Gastroesophagea... Stomach Neoplas... Colorectal Neop... Exocrine Pancre... Appendiceal Ade... Pseudomyxoma Pe...	SGN-STNV	18 Years -	Seagen Inc.
Genetics of Appendix Cancer Study	NCT05734430	Appendix Cancer Appendiceal Can... Appendiceal Neo... Appendiceal Muc... Appendiceal Ade... Appendiceal Car... Appendiceal Neo... Appendix Adenoc... Appendix Mucino... Appendix Tumor Appendix Cancer... Appendix NET Low-Grade Appen... High Grade Appe... High Grade Appe...	Genetic profili... Retrospective t...	18 Years -	Vanderbilt-Ingram Cancer Center
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors	NCT06399757	Colorectal Canc... Cholangiocarcin... Appendiceal Ade... Pancreatic Aden... Gastric Adenoca... Endometrial Ade... Triple Negative... Ovarian Cancer Prostate Cancer	APL-5125	18 Years -	Apollo Therapeutics Ltd

Spots Global Cancer Trial Database for appendiceal adenocarcinoma